I-Mab Biopharma (IMAB) Misses Q3 EPS by 4c

I-Mab Biopharma (NASDAQ: IMAB) reported Q3 EPS of ($0.11), $0.04 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on I-Mab Biopharma (IMAB) click here.

You May Also Be Interested In

• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• JPMorgan Upgrades Taiwan Mobile Co Ltd (3045:TT) to Overweight
• Sk Hynix Union Is Finalising Wording Of Tentative Wage Deal, And Will Brief Its Members On The Terms This Afternoon- Reuters